EMD 121974 in Treating Patients With Advanced Solid Tumors

Inclusion Criteria

• •Histologically confirmed solid tumor that is refractory to standard therapy or for which no standard therapy exists
• •Tumors must be amenable to minimally-invasive biopsy (i.e., tumors must be superficial enough to be sampled by punch biopsy or core biopsy procedure without radiologic guidance)\*
• •No uncontrolled brain metastases, including symptomatic lesions or lesions requiring glucocorticoids and/or anticonvulsants to suppress symptoms
• •* Negative brain scan required if there are signs and symptoms suggestive of brain metastasis
• •Performance status - ECOG 0-2
• •Performance status - Karnofsky 60-100%
• •At least 12 weeks
• •WBC at least 3,000/mm\^3
• •Absolute neutrophil count at least 1,500/mm\^3
• •Platelet count at least 100,000/mm\^3
• •Hemoglobin at least 9 g/dL
• •Bilirubin normal
• •AST and ALT no greater than 2.5 times upper limit of normal
• •Creatinine normal
• •Creatinine clearance at least 60 mL/min
• •No symptomatic congestive heart failure
• •No unstable angina pectoris
• •No ongoing or active infection
• •No other concurrent serious systemic disorders (e.g., significant CNS illness) that would preclude study
• •No concurrent psychiatric illness or social situations that would preclude study
• •Not pregnant or nursing
• •Negative pregnancy test
• •Fertile patients must use effective contraception
• •No other concurrent anticancer immunotherapy
• •Concurrent hematologic growth factors for cytopenias allowed
• •At least 4 weeks since prior anticancer chemotherapy (6 weeks for nitrosoureas, carmustine, or mitomycin) and recovered
• •See Disease Characteristics
• •No concurrent anticancer hormonal therapy
• •Concurrent oral contraceptives or postmenopausal hormone replacement allowed
• •Recovered from prior radiotherapy
• •At least 2 weeks since prior palliative radiotherapy to bone or brain metastases
• •At least 4 weeks since prior anticancer radiotherapy
• •No concurrent anticancer radiotherapy
• •Not specified
• •At least 4 weeks since prior anticancer therapy and recovered
• •At least 4 weeks since prior investigational agents
• •Any number of prior therapies allowed
• •No other concurrent anticancer investigational or commercial agents
• •No concurrent combination antiretroviral therapy for HIV-positive patients